Changing pattern of presentation in monoclonal gammopathy of undetermined significance: A single-center experience with 1400 patients

Medicine

Volumn 89, Issue 4, 2010, Pages 211-216

  Varettoni, Marzia ^a   Corso, Alessandro ^a   Cocito, Federica ^a   Mangiacavalli, Silvia ^a   Pascutto, Cristiana ^a   Zappasodi, Patrizia ^a   Pica, Gianmatteo ^a   Lazzarino, Mario ^a  

^a UNIVERSITY OF PAVIA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN; BETA 2 MICROGLOBULIN; HEMOGLOBIN; IMMUNOGLOBULIN M; M PROTEIN;

ADULT; AGED; ARTICLE; BONE MARROW CELL; CLINICAL EVALUATION; CLINICAL FEATURE; CONTROLLED STUDY; FEMALE; HUMAN; LIFE EXPECTANCY; MAJOR CLINICAL STUDY; MALE; MONOCLONAL IMMUNOGLOBULINEMIA; OUTCOME ASSESSMENT; PRIORITY JOURNAL;

ADULT; AGE DISTRIBUTION; AGED; AGED, 80 AND OVER; DISEASE PROGRESSION; FEMALE; HUMANS; MALE; MIDDLE AGED; PARAPROTEINEMIAS; PREVALENCE; RETROSPECTIVE STUDIES; RISK FACTORS;

EID: 77954712591     PISSN: 00257974     EISSN: None     Source Type: Journal    
DOI: 10.1097/MD.0b013e3181e763be     Document Type: Article

References (20)

1. Axelsson U, Bachmann R, Hällén J. Frequency of pathological proteins (M-components) in 6,995 sera from an adult population. Acta Med Scand. 1966;179:235-247.
2. Baldini L, Guffanti A, Cesana BM, Colombi M, Chiorboli O, Damilano I, Maiolo AT. Role of different hematologic variables in defining the risk of malignant transformation in monoclonal gammopathy. Blood. 1996;87:912-918.
3. Bladé J, Lopez-Guillermo A, Rozman C, Cervantes F, Salgado C, Aguilar J, Vives-Corrons JL, Montserrat E. Malignant transformation and life expectancy in MGUS. Br J Haematol. 1992;81:391-394.
4. Bladé J, Rosiñol L, Cibeira MT, de Larrea CF. Pathogenesis and progression of monoclonal gammopathy of undetermined significance. Leukemia. 2008;22:1651-1657.
5. Cesana C, Klersy C, Barbarano L, Nosari AM, Crugnola M, Pungolino E, Gargantini L, Granata S, Valentini M, Morra E. Prognostic factors for malignant transformation in monoclonal gammopathy of undetermined significance and smouldering multiple myeloma. J Clin Oncol. 2002;20:1625-1634.
6. Go RS, Doyle LM. A monoclonal gammopathy in search of clinical significance: 57 years later. Blood. 2009;114:2355-2356.
7. Gregersen H, Mellemkjaer L, Ibsen JS, Dahlerup JF, Thomassen L, SLrensen HT. The impact of M-component type and immunoglobulin concentration on the risk of malignant transformation in patients with monoclonal gammopathy of undetermined significance. Haematologica. 2001;86:1172-1179.
8. Gregersen H, Ibsen J, Mellemkjoer L, Dahlerup J, Olsen J, SLrensen HT. Mortality and causes of death in patients with monoclonal gammopathy of undetermined significance. Br J Haematol. 2001;112:353-357
9. International Myeloma Working Group. Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: a report of the International Myeloma Working Group. Br J Haematol. 2003;121:749-757.
10. Kristinsson SY, Biörkholm M, Andersson M-L, Eloranta S, Dickman PW, Goldin LR, Blimark C, Mellqvist U-H, Wahlin A, Turesson I, Landgren O. Patterns of survival and causes of death following a diagnosis of monoclonal gammopathy of undetermined significance (MGUS) a population-based study. Haematologica. 2009;94:1714-1720.
11. Kyle RA, Therneau TM, Rajkumar SV, Offord JR, Larson DR, Plevak MF, Melton LJ. A long-term study of prognosis in monoclonal gammopathy of undetermined significance. N Engl J Med. 2002;346:564-569.
12. Kyle RA, Therneau TM, Rajkumar SV, Larson DR, Plevak MF, Offord JR, Dispenzieri A, Katzmann JA, Melton Iii LJ. Prevalence of monoclonal gammopathy of undetermined significance. N Engl J Med. 2006;354:1362-1369.
13. Morra E, Cesana C, Klersy C, Varettoni M, Cavanna L, Canesi B, Tresoldi E, Barbarano L, Lazzarino M. Predictive variables for malignant transformation in 452 patients with asymptomatic IgM monoclonal gammopathy. Semin Oncol. 2003;30:172-177.
14. Papadopoulos NM, Elin RJ, Wilson DM. Incidence of gamma-globulin banding in a healthy population by high-resolution electrophoresis. Clin Chem. 1982;28:707-708.
15. Rajkumar SV, Kyle RA, Therneau TM, Melton Iii LJ, Bradwell AR, Clark RJ, Larson DR, Plevak MF, Dispenzieri A, Katzmann JA. Serum free light chain ratio is an independent risk factor for progression in monoclonal gammopathy of undetermined significance. Blood. 2005;106:812-817.
16. Rosinol L, Cibeira T, Montato S, Rozman M, Esteve J, Filella X, Blade J. Monoclonal gammopathy of undetermined significance: predictors of malignant transformation and recognition of an evolving type characterized by a progressive increase in M protein size. Mayo Clin Proc. 2007;82:428-434.
17. Rossi F, Petrucci MT, Guffanti A, Marcheselli L, Rossi D, Callea V, Vincenzo F, De Muro M, Baraldi A, Villani O, Musto P, Bacigalupo A, Gaidano G, Avvisati G, Goldaniga M, Depaoli L, Baldini L. Proposal and validation of prognostic scoring systems for IgG and IgA monoclonal gammopathies of undetermined significance. Clin Cancer Res. 2009;15:4439-4445.
18. Schaar CG, le Cessie S, Snijder S, Franck PF, Wijermans PW, Ong C, Kluin-Nelemans H. Long-term follow-up of a population based cohort with monoclonal proteinaemia. Br J Haematol. 2009;144:176-184.
19. Sinclair D, Sheehan T, Parrott DM, Stott DI. The incidence of monoclonal gammopathy in a population over 45 years old determined by isoelectric focusing. Br J Haematol. 1986;64:745-750.
20. Van de Poel MHW, Coebergh JW, Hillen HF. Malignant transformation of monoclonal gammopathy of undetermined significance among out-patients of a community hospital in southeastern Netherlands. Br J Haematol. 1995;91:121-125.